Filtered By:
Infectious Disease: Influenza
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 693 results found since Jan 2013.
Sex differences in antibody responses to the 23-valent pneumococcal polysaccharide vaccination
There are profound sex-based differences in both humoral and cellular immune responses to vaccination [1]. In general, adult females demonstrate higher antibody responses to bacterial and viral vaccines than men [2]. For instance, adult females vaccinated with half the dose of the trivalent inactivated influenza vaccine (TIV) produce similar humoral immune responses than adult males vaccinated with a full dose of the TIV [3]. Given that the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is an important tool in our evaluation of the humoral immune response [4], we sought to determine if men and women have a signific...
Source: Annals of Allergy, Asthma and Immunology - July 19, 2021 Category: Allergy & Immunology Authors: Sergio E. Chiarella, Sarah M. Jenkins, Miguel A. Park, Roshini S. Abraham, Avni Y. Joshi Tags: Letters Source Type: research
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Eosinophils in antiviral immunity and (perhaps) a benefit of having asthma during the SARS-CoV2 pandemic
Eosinophils are potent proinflammatory leukocytes defined by their expression of preformed cationic granules. Eosinophils have historically primarily been understood to have evolved to mediate toxic immune responses to parasites, while, more problematically, being toxic to airway epithelial cells and other healthy tissues.1 Recently, however, a role of eosinophils in eliminating viral pathogens has emerged, including studies reporting the contribution of eosinophils in the elimination of respiratory syncytial virus (RSV), influenza, parainfluenza and, rhinovirus.
Source: Annals of Allergy, Asthma and Immunology - July 1, 2021 Category: Allergy & Immunology Authors: Ryan Eid, Larry Borish Tags: Editorial Source Type: research
COVID-19 Pandemic and Influenza Season in Hospitalized Patients: Concerns and Suggestions
Iran J Allergy Asthma Immunol. 2021 Jun 6;20(3):382-383. doi: 10.18502/ijaai.v20i3.6340.ABSTRACTThis is a letter to the editor.PMID:34134459 | DOI:10.18502/ijaai.v20i3.6340
Source: Iranian Journal of Allergy, Asthma and Immunology - June 17, 2021 Category: Allergy & Immunology Authors: Amir Hossein Norooznezhad Source Type: research
